Towards AI-Enabled Multimodal Diagnostics and Management of COVID-19 and Comorbidities in Resource-Limited Settings

Olawande Daramola 1,*, Peter Nyasulu 2, Tivani Mashamba-Thompson 3, Thomas Moser 4, Sean Broomhead 5, Ameera Hamid 5, Jaishree Naidoo 6, Lindiwe Whati 7, Maritha J. Kotze 8, Karl Stroetmann 9 and Victor Chukwudi Osamor 10

Abstract: A conceptual artificial intelligence (AI)-enabled framework is presented in this study involving triangulation of various diagnostic methods for management of coronavirus disease 2019 (COVID-19) and its associated comorbidities in resource-limited settings (RLS). The proposed AI-enabled framework will afford capabilities to harness low-cost polymerase chain reaction (PCR)-based molecular diagnostics, radiological image-based assessments, and end-user provided information for the detection of COVID-19 cases and management of symptomatic patients. It will support self-data capture, clinical risk stratification, explanation-based intelligent recommendations for patient triage, disease diagnosis, patient treatment, contact tracing, and case management. This will enable communication with end-users in local languages through cheap and accessible means, such as WhatsApp/Telegram, social media, and SMS, with careful consideration of the need for personal data protection. The objective of the AI-enabled framework is to leverage multimodal diagnostics of COVID-19 and associated comorbidities in RLS for the diagnosis and management of COVID-19 cases and general support for pandemic recovery. We intend to test the feasibility of implementing the proposed framework through community engagement in sub-Saharan African (SSA) countries where many people are living with pre-existing comorbidities. A multimodal approach to disease diagnostics enabling access to point-of-care testing is required to reduce fragmentation of essential services across the continuum of COVID-19 care.

Keywords: artificial intelligence; COVID-19; resource-limited settings; multimodal diagnostics; diagnostics; machine learning; Explainable AI; point-of-care

1. Introduction

Countries in Sub-Saharan Africa (SSA) have been affected by the novel coronavirus 2019 (COVID-19) infection with severe impacts on the people, health systems, and their economies. Many cases of COVID-19 in SSA countries have associated comorbidities such
as tuberculosis (TB), HIV/AIDS, diabetes, hypertension, and malaria. Cases of COVID-19 and associated comorbidities are more difficult to manage and have resulted in more deaths [1].

South Africa, Ethiopia, Kenya, and Nigeria are the countries with the highest number of reported COVID-19 cases in SSA [2]. These countries also have a large population of persons with comorbidities such as HIV, TB, and diabetes. In terms of absolute numbers, South Africa has 7.7 million people living with HIV, the highest number in the world. HIV remains prevalent in the population with approximately 20% of people infected with HIV. There is a large number of people with HIV/TB co-infection in South Africa, where TB is recognized as a high burden disease. In 2018, an estimated 63,000 people were reported to have died from active TB, out of which 42,000 were HIV positive. Yearly, TB remains the largest contributor to death in South Africa [3]. Nigeria, with 1.9 million people living with HIV, has the fourth-largest HIV epidemic in the world in term of absolute numbers. Nigeria also has the fourth-largest TB epidemic in the world, with cases of HIV/TB co-infection on the rise. Apart from HIV/AIDS, cases of drug-resistant TB are prevalent in Nigeria. An estimated 407,000 die of TB each year in Nigeria, out of which an estimated 39,000 are HIV positive people [4].

Thus, the existence of a large population of people with comorbidities in SSA countries makes it more difficult to manage cases of COVID-19 worsened by co-infection. For these types of patients, it is more difficult to determine the pattern of progression of their pre-existing conditions in the presence of COVID-19 and the impact these comorbidities have on the best form of personalized care that is required to treat them for their COVID-19 infection [5,6]. Currently, difficulties exist in the area of active case finding due to weak disease surveillance infrastructures, low testing capacity particularly in rural areas, and many RLS in these countries. Additionally, there are delays in the treatment of detected active cases because the traditional healthcare system infrastructures in these countries are overstretched. Experiences from the COVID-19 pandemic in South Africa reveal that cases with comorbidities such as HIV, TB, diabetes, and hypertension were more complicated and difficult to manage [1]. There is limited access to point-of-care (POC) testing and a lack of effective disease surveillance in RLS, which has accounted for a relatively low number of reported COVID-19 cases [7,8]. For example, in South Africa, a significantly greater number of COVID-19 cases have been reported in the more developed provinces such as Western Cape, and Gauteng, compared to more rural provinces such as Limpopo and Eastern Cape with low testing capacity, partly due to inadequate resources. This pattern is repeated in many other SSA countries. The problem of limited access to POC testing opportunities and lack of an effective surveillance system remain major public health challenges that limit timely interventions to contain threats of infectious diseases in SSA.

This scenario makes the need for a multimodal approach to disease diagnostics to increase accessibility to POC testing by different categories of people compelling. It is also essential that the results of diagnostics from diverse sources are effectively harnessed through digital technology to enable effective disease surveillance and clinical management of identified cases. So far, digital health in Africa has been implemented at various levels of maturity and sophistication across regions and countries in SSA, which makes the deployment of digital solutions in many settings difficult. Problems exist in the area of lack of quality data and data curation mechanisms, lack of integration platforms to harness data from relevant sources, poor technology infrastructure, lack of coordination, and generally low digital technology diffusion [9,10].

There is a need to facilitate the integration of patient data from different sources and disparate health platforms by ensuring their interoperability, which will create the basis for data merging, and thereupon the application of artificial intelligence (AI) methods for gaining improved tools for better healthcare in SSA. The augmentation of existing traditional diagnostic and treatment approaches with AI-derived insights will alleviate some of the existing challenges particularly in the resource-limited settings of SSA. This includes, for example, the novel pathology-supported genetic testing (PSGT) approach [11] implemented
in South Africa as a case study using the framework recently described by 38 researchers across the African continent (https://www.aasciences.africa/publications/policy-paper-framework-implementation-genomic-medicine-public-health-africa (accessed on 6 September 2021). The capacity of AI technology to augment sound decision-making using PSGT in patients stratified by body mass index [12] and other forms of data (text, image, audio)—be they real-time, recent or older—makes it a viable tool to supplement the capabilities of healthcare systems in SSA in the fight against COVID-19, other highly prevalent infectious diseases, and future pandemics.

The rest of this paper is structured as follows. Section 2 describes the technological challenge and the objectives of the framework. In Section 3, we present the methodology adopted for the design of the framework, while Section 4 discusses the merits of the framework. The paper is concluded in Section 5 with a brief outlook and future work envisaged.

2. The Technological Challenges and Objectives of the Framework

This section briefly presents the technological challenges from the perspective of recent trends identified in the literature and the objectives of the proposed framework using PSGT as a case study of genetic knowledge integration [11].

2.1. The Technological Challenge

Despite the promise of AI and digital technology in advancing infectious disease treatment [8], there is limited evidence on the successful application of AI and digitally connected point-of-care (POC) diagnostics for infectious diseases and associated comorbidities, particularly in rural settings in SSA with a high burden of disease. RLS are characterised by poor and inadequate healthcare infrastructures, shortages of qualified medical personnel, poverty, lack of access to technology, and high cost of healthcare in general [9]. Lately, there has been more interest in smartphone-based POC testing and related diagnostic support that could be suitable for RLS, but few of these applications have been successfully applied and sustained in SSA [13]. The high number of cases of COVID-19 in SSA and the low POC testing capacity in RLS make multiple POC diagnostic approaches that are sufficiently robust, accurate, and readily accessible to different categories of people living in RLS necessary. Increased access to POC testing will engender early detection as well as prompt treatment of cases, and thereby more efficient outbreak control. The potential to generate diverse types of data from various POC diagnostics and other patient data sources for larger populations creates an opportunity to explore the potential of AI-based novel approaches to facilitate and support better healthcare in RLS. Various types of data that may be available per time in a resource-limited setting including pathology data, genomics data, radiological image data, end-user/patient provided data, and electronic medical records will be collected. The types of available data will inform the AI-enabled integration of patient-centred diagnostic methods that are used with a focus on the most common COVID-19 comorbidities underpinned by genomic pathways coincident with the SARS-CoV-2 viral disease [14]. These include the APOE-cholesterol, MTHFR-homocysteine, FII/FV-blood clotting, and HFE-iron metabolism pathways [15] recently combined into a novel POC test kit (https://gtr.ukri.org/projects?ref=103993, accessed on 6 September 2021) for non-communicable diseases (NCDs) ranging from Alzheimer’s disease to cancer and cardiovascular disease (CVD). Thus, this study proposes an AI-enabled framework for multimodal diagnostics of COVID-19 and associated comorbidities at POC to improve access to improved clinical management in resource-limited settings in SSA.

2.2. Objectives of the Proposed Framework

We seek to create an AI-based technical framework that will enable the integration of data from various POC diagnostic approaches for the improved treatment of COVID-19 patients and their associated comorbidities. The better management of COVID-19 cases will entail the flagging of relevant information for prescribing more personalized
treatments, predicting the probable pattern of disease progression, and handling post-treatment complications reported by patients. Furthermore, a component of this framework will provide smart and cost-effective disease surveillance tools for RLS within the given regional area of the healthcare providers involved. The framework will be a low-cost, easy-to-implement solution. It will be generic, thereby usable—after localization and adaptation—in many RLS in SSA.

Specifically, the AI framework will enable the following tasks:

1. Collection of real-world evidence, particularly on diagnosis and treatment of COVID-19 patients
2. Creation of an integrated platform for harnessing data from various POC diagnostic methods, including medical imaging-based diagnostics and healthcare IT systems
3. Effective decision-making based on screening algorithms informing differential diagnosis and management of COVID-19-associated comorbidities in community-based health services in RLS
4. Mobile phone-based contact tracing for COVID-19 and associated comorbidities
5. PSGT combining diagnostic RNA-based SARS-CoV-2 testing with DNA-based chronic disease screening for managing potential biochemical abnormalities caused by gene-environment interaction.

The following self-reporting scenario is presented as an example of the PSGT algorithm being developed for feedback to patients by a healthcare practitioner: A patient experiences a reinfection with SARS-CoV-2 [16] three weeks after COVID-19 vaccination (Pfizer, first injection). It concerns a 63-year-old female first diagnosed with asymptomatic COVID-19 pre-surgery in June 2020, which supports the incorporation of COVID-19 status in the patient report. As shown in Table 1, PSGT typically starts with an online questionnaire-based health check including the assessment of body mass index (BMI) and metabolic syndrome features targeting dyslipidaemia associated with COVID-19 severity and comorbidities. Involvement of this NCD pathway known to be influenced by lifestyle and other environmental factors, which in turn may trigger genetic risk such as the APOE e4 allele identified in this case, should be addressed to prevent cumulative causal effects [17,18]. Vaccine-related adverse effects are typically linked to old age [19] and pre-existing obesity, diabetes, or significant allergies. These are the high-risk subgroups we hope to identify at entry into the multimodal risk management programme for optimal treatment guided by our ever-increasing knowledge base developed in an ongoing way as new discoveries are reported in the literature [20].

Table 1. Interpretative commenting on the pathology-supported genetic testing performed (April 2011) in the symptomatic COVID-19 reinfected patient based on self-data reporting (July 2021) for clinical follow-up by the treating physician.

| Weight Management and Your Health |   |
|-----------------------------------|---|
| Overweight-BMI > 26 kg/m²         | Your body mass index (BMI) that provides a measure of height in relation to weight (kg/m²) is above the ideal range of between 18.5 and 24.9 kg/m². The BMI is only one indicator of a healthy weight and should therefore be monitored together with skinfold measurements and the percentage body fat to achieve and maintain your target weight. |
| Chronic inflammation              | Fat accumulation needs to be avoided as it is accompanied by low-grade inflammation, which results in resistance to weight loss. This is very important due to the detection of a genetic variation (APOE e4 allele) involved in both cholesterol/fat metabolism and inflammation. |
| Metabolic syndrome risk           | Being overweight or obese is associated with an increased risk for the metabolic syndrome, which is caused by a combination of 3 or more of the following features: central obesity, hypertension, insulin resistance and/or dyslipidaemia as may be reflected by high triglycerides and/or low HDL-cholesterol levels. |
Table 1. Cont.

| Optimise Your Diet |
|--------------------|
| Fat intake-Low (excellent) | Maintain the overall low intake of fat reported. High total fat, especially trans-fats and saturated fat intake, correlates with increased body weight and an abnormal lipid profile. Incorporate healthy fats in your diet regularly. Phospholipids will help maintain brain health, which is of concern due to the genetic variation detected. Phospholipid supplements in the form of lecithin or its other forms, phosphatidylcholine and phosphatidylycerine, are available. Good food sources are milk, shellfish, and egg yolk. |
| Folate intake-Low | The daily amount of folate required in the diet differs between individuals according to their genetic make-up and health status. The low folate score (<14) identified correlates with increased homocysteine and body mass index. Ensure a minimum intake of 400 ug folate per day together with adequate amounts of vitamin B6, B12, and riboflavin. Green leafy vegetables (e.g., spinach, broccoli, asparagus), fresh orange juice, and dried beans are good sources. |

| Improve Your Lifestyle |
|------------------------|
| Physical activity-Moderate | Ensure regular participation in sporting activities (e.g., running, jogging, walking, swimming) and/or follow a moderate exercise program for at least 30–60 min most days of the week. Physical activity promotes blood circulation and vascular health aimed at prevention of dementia/Alzheimer’s disease with advanced aging, especially in genetically susceptible individuals. |

| Monitor Your Blood Levels |
|---------------------------|
| Lipid Profile-Not provided | Keeping cholesterol and triglyceride levels within the normal ranges is very important due to a genetic hyper-responsiveness to lifestyle risk factors. Measurement of these levels is recommended to determine gene expression and to monitor response to treatment. |

| Optimise Your Treatment Program |
|---------------------------------|
| Family Medical Conditions: |
| - Alzheimer’s disease |
| - Coronary heart disease |
| - Personal Medical Conditions: |
| - Insulin resistance |
| - Sleep problems |
| Medical History (Reported at referral in 2011) | A medical condition reported in more than one generation indicates a strong familial risk, especially when diagnosed at a relatively young age. |
| Genetic variation affecting inflammation/blood clotting | Intake of at least 1–2 g omega-3 fatty acids per day may be advisable, especially when intake of dietary sources (e.g., oily fish) is inadequate. A ratio of 2:1 to 3:1 for omega-6 and 3 is recommended. Intake of omega-6 is generally too high in most populations; therefore, fish or fish oil supplements are the preferred sources for increasing omega-3 fatty acid intake when omega-6 intake is adequate. Certain foods such as milk and eggs are fortified with omega-3s and are also recommended. It is important to note that supplementation with omega-3 fatty acids and other nutrients may affect the response to certain medications (e.g., warfarin, chemotherapy). |
| Genetic variation indicating altered nutritional requirements for your genotype | Adequate daily intake of vitamins and minerals [21] required as enzyme co-factors with additional intake of antioxidants is advisable in the presence of the APOE gene variation linked to COVID-19 infection, severity, and co-morbidities [22]. |

3. Materials and Methods

The conceptual design of the proposed AI-enabled framework for multimodal diagnostics of COVID-19 is informed by the set of requirements that have been identified as critical for the practical realization of the envisioned framework requiring integration of data from different health sources. In this Section, these requirements, the conceptual architecture, and a description of key aspects of the architecture are presented.
3.1. Requirements of the AI-Enabled Framework for Multimodal Diagnostics of COVID-19

The proposed framework is envisioned to provide end-to-end support for the management of COVID-19 and pandemic situations. It will support self-data capture, case data capture, explanation-based intelligent recommendations for patient triage, disease diagnosis, patient treatment, contact tracing, and case management. Communication with end-users in local languages through cheap and accessible means such as WhatsApp/Telegram, social media, and SMS are also supported. The key activities that will be supported by the framework include:

1. Data collection from patients on symptoms of COVID-19 that have been observed. This will be performed by using diverse sources such as interaction with health care workers via the phone, SMS messaging, WhatsApp messages/call, Telegram message/call. The information collected will be limited to issues relating to COVID-19 and will be stored on a secure system. The security of electronic health records (EHR) during transmission from one point to another shall be secured by using credible encryption methods. The options to consider include the use of scrambled alpha-numeric randomization combined with RSA, as we did in a previous study [23].
2. Case documentation by health care workers (HCW) through a mobile app, webform
3. Capture of radiological images from patients
4. Access and integration with electronic medical records
5. Prediction of disease using machine learning (ML)
6. AI-generated recommendations with explanations for HCW
7. Delivery of AI-generated suggestions to patients through mobile phone via personal calls, SMS messaging, WhatsApp, Telegram, Mobile App. Messages can be conveyed directly through these means, or via a phone call by the HCW
8. Regular monitoring of patients (under self-quarantine)
9. Aiding decision-making on patient triage and treatment schedule
10. Data analytics and reporting for pandemic management by health management systems (Dashboard reporting)—hotspots, cases per community, neighbourhoods, regions
11. Contact tracing application based on Bluetooth technology that can track close contact with infected persons (only phone numbers are stored on patient’s mobile phone). The application will be triggered by user consent, and stored content is also shared by user consent.

3.2. Architecture of the Proposed Framework for Multimodal Diagnostics of COVID-19

The conceptual architecture of the proposed framework (shown in Figure 1) is influenced by the objectives of the framework. It consists of an integration of existing health systems and components that will enable data from multiple sources and data inputs from various stakeholders to be harnessed for AI-supported decision-making. The self-data capture (1) component allows all data inputs from the patient/user to be collected using the most accessible means for the user. This includes messages sent from a webform, WhatsApp or Telegram, or a voice call in a local language or English. The case data capture (2) component will enable health care workers (HCW) to input all forms of data that pertain to a patient that has been captured through interrogation, clinical examination, or point-of-care testing (PCR-based test, genetic-based testing (PSGT) data, X-ray imaging). All the data from the different sources will be retrieved from the cloud data server by the AI engine component to generate a diagnostic report (3), which will be reviewed by the HCW. Based on the diagnostic report, appropriate information will be sent to the user/patient as the feedback report (4). The feedback could be sent automatically as authorized by the HCW or conveyed personally to the user. An information dashboard (5) that highlights the state of the pandemic, such as case statistics, infection hotspots, surveillance reports, etc., will also be updated regularly based on information that is generated from cases that have been handled via the framework. The AI-enabled framework will rely on the integration of
available public health records, accessible private health records, and archival data sources that are available and accessible nationally.

3.3. Description of the Workflow and Configuration of the AI Engine

Let us consider a hypothetical case example of Mrs. AA, whose COVID-19 related data include the following:

a. Socio-demographic and lifestyle characteristics (e.g., age, gender, ethnicity, residential area, occupation, workplace, smoking status, alcohol use, drug use)
b. Exposure history and symptoms (record of the previous contact with infected persons or places; symptoms types, level of severity of symptoms)
c. Comorbidity profile (such as hypertension, COPD, diabetes, heart diseases, TB, and HIV, as well as severity level of the comorbidity)
d. Medical imaging data such as CXR, chest CT of Mrs. AA
e. Laboratory test data such as FBC, ferritin, PCT, MicroRNAs, NT-proBNP, and inflammatory cytokines)
f. Data obtained for PSGT to customise feedback to Mrs. AA based on personal utility and clinical relevance (see Table 1).
g. Vaccine and other Medication data (e.g., steroids, antibiotics, antiviral, antifungal, medication for glycaemic control, antihypertensive)
We now describe how the AI engine can process the data so that a result can be generated by the proposed framework. The AI engine consists of six aspects that determine its workflow (see Figure 2). These are data collection and pre-processing (1), feature extraction and data modelling (2), dataset repository (3), model training (4), explainable recommendations (5), and model evaluation (6). These aspects are described below:

3.3.6. Model Evaluation
The performance of the selected ML models in terms of accuracy of prediction will be evaluated by using standard metrics for regression, classification, and recommendation algorithms. The quality of explanation can also be evaluated. The evaluation metrics are mainly quantitative metrics that will be used to assess the performance of AI results by using human expert judgement as a gold standard. The usability, reliability, and trustworthiness assessment of the AI will be conducted through field trials that capture the perspective of individuals that have used the system to support their operations.

3.4. Utilization of Generated Results
The generated result and explanation will be sent to the HCW for approval. If, after review, the generated result and explanation are approved by the HCW, then they will be sent to the patient directly by the system or relayed to the patient by the HCW through the most accessible means to reach the patient. This could be via WhatsApp, Telegram, SMS, or a phone call.

Figure 2. The architecture of the AI engine of the proposed framework for multimodal diagnostics and management of COVID-19 and comorbidities.

3.3.1. Data Collection and Pre-Processing
i. Archived but anonymized data of patients (like Mrs. AA) with COVID-19 cases are collected from diverse sources—hospital records, medical records databases in South Africa. This similarly applies to any other country in SSA.
ii. The collected data are labelled by using descriptive attribute names that depict the information that they represent. For example, if the objective is to predict the possibility of COVID-19 infection, COVID-19 death, or COVID-19 recovery, then the dependent attributes such as age profile, gender type, symptom severity profile, comorbidity profile, the severity of comorbidity disease, weight profile, blood profile, genetic data, etc. that can influence specific patient outcomes such as infection, death, recovery, survival must be identified and appropriately labelled. The process will be a combination of manual and automated data labelling depending on the inherent quality of collected initial data.
iii. Data pre-processing will be performed to clean up the data, fix missing values, and balance the dataset (if necessary) to reduce bias. Instances of missing numeric values can be replaced by the median or the mean value (for data with a normal distribution), while missing categorical values can be replaced by the mode. When there is an imbalanced dataset due to the under-representation of a specific class, class balancing techniques such as the synthetic minority oversampling technique (SMOTE) [24] will be used to generate additional synthetic data to ensure a balanced dataset.

3.3.2. Feature Extraction and Data Modelling

iv. Data points of interest (features) are extracted from the main database. This will include important biodata such as age, gender, address, demographic data, and key clinical information that pertain to the patient category concerned.

v. Mapping of observed symptoms in patients with COVID-19 and specific morbidities will be performed. This will entail documenting symptoms that are associated with particular instances of COVID-19 and comorbidity. This will seek to answer the question of how the symptomatic patterns of COVID-19 plus HIV are different/similar to those of COVID-19 plus diabetes, for example. This process will allow different patients’ symptomatic profiles to be generated, e.g.:

- COVID-19 + HIV; COVID-19 + TB symptoms
- COVID-19 + HIV + TB symptoms; COVID-19 + diabetes (DB) symptoms
- COVID-19 + hypertension symptoms; COVID-19 + hypertension + DB
- COVID-19 + malaria; COVID-19 + malaria + HIV; COVID-19 + etc.

3.3.3. Dataset Repository

vi. Based on the feature extraction in Step 4 and Step 5, different datasets will be created. It will be possible to filter the created datasets based on some parameters such as date, type of morbidity, age, demography, symptomatic pattern, and other dimensions that are of interest in order to create sub-datasets and variant datasets by using querying techniques. Data can be extracted using SQL statements to create sub-datasets. Examples of different SQL queries that can be used to extract different sub-datasets are shown in Table 2.

| S/n | Task | Query Statements |
|-----|------|------------------|
| 1   | Extract data on cases of COVID-19 + TB | SELECT All from Database where Case = 'COVID-19' AND comorbidity = 'TB' |
| 2   | Extract data on cases of COVID-19 + HIV + TB | SELECT All from Database where Case = 'COVID-19' AND (comorbidity = 'TB' AND comorbidity = 'HIV') |
| 3   | Extract data on cases of COVID-19 + comorbidity for males that are 60 years and older | SELECT All from Database where Case = 'COVID-19' AND (comorbidity = 'TB' OR comorbidity = 'Diabetes' OR comorbidity = 'HIV' OR comorbidity = 'Malaria') AND (gender = 'Male') AND (age ≥ 60) |

3.3.4. Model Training

vii. Supervised machine learning algorithms (ANN, SVM, deep neural networks, ensemble models—random forest, extreme gradient boosted trees (XGBoost), bagging-gradient boosted trees (B-GBT), etc.) are trained based on selected datasets from the dataset repository and the type of prediction that is required to be made per time. Appropriate hyperparameter tuning methods such as cross-validation and regularization shall be applied to prevent overfitting during training and better generalization of trained ML models. Methods such as k-fold validation, dropout regularization, ridge regression regularization (L2-norm), lasso regression regularization (L1-norm),
entropy regularization, and noise injection are good options that shall be explored to achieve this [25]. Experiments on batch training using gradient descent algorithms and minibatch training with stochastic gradient descent using different activation functions shall also be performed to ensure that the most efficient methods are used for training so that the best-trained models are eventually used for predictions [26].

viii. Trained predictive models are stored in the cloud-based machine learning server.

ix. The most important features of trained models (highest weighted) are also stored. For tree-based ML models such as decision tree, random forest, extreme gradient boosted trees (XGBoost), and bagging-gradient boosted trees (B-GBT), this can be obtained from the feature importance property of the tree model [27]. For regression models, this could be obtained by using univariate selection, while for other ML models, dimensionality reduction methods such as principal component analysis (PCA) can be used to determine feature selection and feature importance [28]. Knowing the most important features of an ML model is particularly useful for the explainability of the ML model, as it reveals the features that have the strongest relationships with the output variable the most [29].

3.3.5. Real-Time Explainable ML-CBR Recommendations by the AI Engine

x. New case data is received that requires prediction.

xi. Required AI operation is selected by the user (HCW). This could be a regression task to estimate something, classify/identify something, or obtain a recommendation.

xii. ML prediction is generated by the AI engine.

xiii. The result of the ML algorithm is sent to a case-based reasoning module (CBR).

a. CBR uses the most important features as a basis to retrieve similar cases to the current case from the case base. The case base is linked to the original dataset used to train the ML model.

b. The feature values of cases that are similar to the current case are used to construct an explanation to justify the prediction generated by the ML model, thereby utilizing a post hoc approach to ensure the explainability of the ML result.

xiv. Every predicted case is stored in the case base for future reuse.

3.3.6. Model Evaluation

The performance of the selected ML models in terms of accuracy of prediction will be evaluated by using standard metrics for regression, classification, and recommendation algorithms. The quality of explanation can also be evaluated. The evaluation metrics are mainly quantitative metrics that will be used to assess the performance of AI results by using human expert judgement as a gold standard. The usability, reliability, and trustworthiness assessment of the AI will be conducted through field trials that capture the perspective of individuals that have used the system to support their operations.

3.4. Utilization of Generated Results

The generated result and explanation will be sent to the HCW for approval. If, after review, the generated result and explanation are approved by the HCW, then they will be sent to the patient directly by the system or relayed to the patient by the HCW through the most accessible means to reach the patient. This could be via WhatsApp, Telegram, SMS, or a phone call.

4. The Merits of the Proposed Framework

This framework was conceived by a consortium of experts in AI, medical sciences, laboratory sciences, and business that cuts across academia and industry. There is a plan to conduct a full-scale study on the applicability of the framework using study sites in South Africa and Nigeria. The implementation of the AI-enabled framework is expected to yield the following merits:
i. Harness the different types of clinically relevant data for decision-making on diagnosis and treatment of COVID-19 and comorbidities;

ii. Enable differentiated and personalised treatment for patients with COVID-19 and comorbidities in terms of patient triage, treatment, and post-infection management;

iii. Use multimodal diagnostic tools to guide the management of patients with COVID-19 and comorbidities (HIV/TB/malaria) during treatment, determining the pattern of disease progression and handling of posttreatment complications;

iv. Use clinical diagnosis from different disciplines to guide management of PRDs in the presence of COVID-19;

v. Determine the possibility of patients with comorbidity developing COVID-19 if there is exposure due to their risk factors;

vi. Generate intelligent and explanation-rich recommendations on detected cases for use by healthcare workers (HCW) to aid decision-making, thus enabling trustworthy AI for healthcare;

vii. Support the process of disease surveillance in RLS through multi-sensory contact tracing, thus helping with outbreak control;

viii. Generate timely analytical reports on key factors that influence spread, infection recovery rates, and other factors of interest; and

ix. Aid the formulation of policies and strategies for containing and combating COVID-19.

5. Conclusions

In this paper, we have presented the conceptual overview and the merits of an AI-based framework for multimodal diagnostics of COVID-19 and its associated comorbidities, which could be applied in RLS in sub-Sharan Africa. The notion of the framework is novel as it is the first that is based on the triangulation of multiple diagnostic methods (in-vivo and molecular-based testing) such that data from several methods can be harnessed through AI to facilitate COVID-19 detection, treatment, and management in RLS. Our immediate next objectives are to source funds for the implementation of this framework and to draw vital lessons of relevance to RLS in Africa and other, similar, contexts in developing countries.

Author Contributions: Conceptualization, O.D., P.N. and T.M.-T.; methodology, O.D., P.N., T.M.-T., T.M., S.B., J.N., M.J.K. and V.C.O.; investigation, O.D., P.N., T.M.-T., T.M., S.B., J.N., M.J.K. and L.W.; writing—original draft preparation, O.D.; writing—review and editing, O.D., M.J.K., L.W., P.N., T.M.-T., V.C.O., A.H. and K.S. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding. The APC was funded by NRF, South Africa and implementation of PSGT by the Technology Innovation Agency of South Africa.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Faculty Ethics Committee (FEC) of the Faculty of Informatics and Design of the Cape Peninsula University of Technology, SA, USA (30 July 2020). For the application of personalised medicine using an integrated service and research approach, the Health and Research Ethics Review Committee of Stellenbosch University, SA, approved assessment of comorbidities and treatment response in COVID-19 cases during follow-up (protocol code N09/08/224-7545, 2 August 2021).

Informed Consent Statement: Informed consent is obtained on a case-by-case basis for implementation of PSGT by a multi-disciplinary healthcare team.

Data Availability Statement: The knowledge database supporting the PSGT case study (Table 1) is available to registered users at https://www.gknowmix.org.

Acknowledgments: We acknowledge Kelebogile E. Moremi at the Division of Chemical Pathology, Stellenbosch University, for her contribution to the incorporation of COVID-19 risk assessment into the PSGT case study. We acknowledge support from the National Research Foundation (NRF), South Africa; the South African Medical Research Council (SAMRC).
Conflicts of Interest: M.J.K. and L.W. are shareholders of Gknowmix (Pty) Ltd., which has developed a genomics database and point-of-care assays using PSGT for research translation under the auspices of the SAMRC. J.N. is a shareholder of EnvisionIT Deep AI Pty LTD, a medical technology company using AI as a clinical decision support tool in imaging diagnosis. The other authors declare no conflict of interest.

References

1. Davies, M.-A. HIV and risk of COVID-19 death: A population cohort study from the Western Cape Province, South Africa. medRxiv 2020. [CrossRef]
2. COVID Live Update: 166,632,552 Cases and 3,460,798 Deaths from the Coronavirus—Worldometer. Available online: https://www.worldometers.info/coronavirus/ (accessed on 22 May 2021).
3. TB Facts—Tests, Drugs, Statistics & Lots more about TB Disease. Available online: http://www.tbfacts.org (accessed on 22 May 2021).
4. TB in Nigeria—Funding, Children, Diagnosing TB, HIV/TB. Available online: https://tbfacts.org/tb-nigeria/ (accessed on 22 May 2021).
5. Chehade, M.J.; Yadav, L.; Jayatilaka, A.; Gill, T.K.; Palmer, E. Personal digital health hubs for multiple conditions. Bull. World Health Organ. 2020, 98, 569–575. [CrossRef] [PubMed]
6. Moyo, S.; Boffa, J.; Mhlaba, T.; Sulis, G.; Sifumbu, Z.; Pai, M.; Daftary, A. COVID-19 and tuberculosis in South Africa: A dangerous combination. S. Afr. Med. J. 2020, 110, 341–342.
7. Kavanagh, M.M.; Erondo, N.A.; Tomori, O.; Dzau, V.J.; Okiro, E.A.; Maleche, A.; Aniebo, I.C.; Rugege, U.; Holmes, C.B.; Gostin, L.O. Access to lifesaving medical resources for African countries: COVID-19 testing and response, ethics, and politics. Lancet 2020, 385, 1735–1738. [CrossRef]
8. Mashamba-Thompson, T.P.; Crayton, E.D. Blockchain and artificial intelligence technology for novel Coronavirus disease-19 self-testing. Diagnostics 2020, 10, 198. [CrossRef]
9. Daramola, O.; Moser, T. Semantic integration of multiple health data for treatment decision-making in low-resource settings. In Proceedings of the Multi Conference on Computer Science and Information Systems. In Proceedings of the MCCSIS 2019—Proceedings of the International Conference on e-Health 2019, Porto, Portugal, 16–19 July 2019.
10. Stroetmann, K.A. Digital Health Ecosystems for African Countries—A Guide for Public and Private Actors for Establishing Holistic Digital Health Ecosystems in Africa; Federal Ministry for Economic Cooperation and Development and Strategic: Bonn, Germany, 2018.
11. Kotze, M.J.; Van Velden, D.P.; Botha, K.; Badenhorst, C.H.; Avenant, H.; Van Rensburg, S.J.; Cronjé, F.J. Pathology-supported genetic testing directed at shared disease pathways for optimized health in later life. Per. Med. 2013, 10, 497–507. [CrossRef]
12. Kwok, S.; Adam, S.; Ho, J.H.; Iqbal, Z.; Turkington, P.; Razvi, S.; Le Roux, C.W.; Soran, H.; Syed, A.A. Obesity: A critical risk factor in the COVID-19 pandemic. Clin. Obes. 2020, 10, e12403. [CrossRef] [PubMed]
13. Liu, J.; Geng, Z.; Fan, Z.; Liu, J.; Chen, H. Point-of-care testing based on smartphone: The current state-of-the-art (2017–2018). Biosens. Bioelectron. 2019, 132, 17–37. [CrossRef] [PubMed]
14. Dolan, M.E.; Hill, D.P.; Mshakherjee, G.; McAndrews, M.S.; Chesler, E.J.; Blake, J.A. Investigation of COVID-19 comorbidities reveals genes and pathways coincident with the SARS-CoV-2 viral disease. Sci. Rep. 2020, 10, 1–11. [CrossRef] [PubMed]
15. Kotze, M. Application of advanced molecular technology in the diagnosis and management of genetic disorders in South Africa. S. Afr. Med. J. 2016, 106, S114–S118. [CrossRef]
16. Cavanaugh, A.M.; Spicer, K.B.; Thoroughman, D.; Glick, C.; Winter, K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1081–1083. [CrossRef] [PubMed]
17. Lückhoff, H.K.; Kidd, M.; van Rensburg, S.J.; van Velden, D.P.; Kotze, M.J. Apolipoprotein E genotyping and questionnaire-based assessment of lifestyle risk factors in dyslipidemic patients with a family history of Alzheimer’s disease: Test development for clinical application. Metab. Brain Dis. 2016, 31, 213–224. [CrossRef] [PubMed]
18. Marais, A.D.; Kotze, M.J.; Raal, F.J.; Khine, A.A.; Talmud, P.J.; Humphries, S.E. Familial hypercholesterolaemia workshop for leveraging point-of-care testing and personalised medicine in association with the Lipid and Atherosclerosis Society of Southern Africa. Cardiovasc. J. Afr. 2019, 30, 297–304. [CrossRef] [PubMed]
19. Wyller, T.B.; Kittang, B.R.; Ranhoff, A.H.; Harg, P.; Myrstad, M. Nursing home deaths after COVID-19 vaccination—Kentucky, May–June 2021. MMWR Morb. Mortal. Wkly. Rep. 2021, 70, 1081–1083. [CrossRef] [PubMed]
20. Sorokin, A.V.; Karathanasis, S.K.; Yang, Z.-H.; Freeman, L.; Kotani, K.; Remaley, A.T. COVID-19-Associated dyslipidemia: Implications for mechanism of paired resolution and novel therapeutic approaches. FASEB J. 2020, 34, 9843–9853. [CrossRef]
21. Kumar, P.; Kumar, M.; Bedi, O.; Gupta, M.; Kumar, S.; Jaiswal, G.; Rabi, V.; Yedke, N.G.; Bijalwan, A.; Sharma, S.; et al. Role of vitamins and minerals as immunity boosters in COVID-19. Inflammopharmacology 2021, 29, 1001–1016. [CrossRef] [PubMed]
22. Kuo, C.L.; Pilling, L.C.; Atkins, J.L.; Masoli, J.A.; Delgado, J.; Kuchel, G.A.; Melzer, D. APOE e4 genotype predicts severe COVID-19 in the UK biobank community cohort. J. Gerontol. A. Biol. Sci. Med. Sci. 2020, 75, 2231–2232. [CrossRef] [PubMed]
23. Osamor, V.C.; Edosomwan, I.B. Employing scrambling alpha-numeric randomization and RSA algorithm to ensure enhanced encryption in electronic medical records. Inform. Med. Unlocked. 2021, 25, 100672. [CrossRef] [PubMed]
24. Gonzalez-Cuautle, D.; Hernandez-Suarez, A.; Sanchez-Perez, G.; Toscano-Medina, L.K.; Portillo-Portillo, J.; Olivares-Mercado, J.; Perez-Meana, H.M.; Sandoval-Orozco, A.L. Synthetic Minority Oversampling Technique for optimizing classification tasks in botnet and intrusion-detection-system datasets. Appl. Sci. 2020, 10, 794. [CrossRef]
25. Nusrat, I.; Jang, S.-B. A comparison of regularization techniques in deep neural networks. Symmetry 2018, 10, 648. [CrossRef]
26. Domingos, E.; Ojeme, B.; Daramola, O. Experimental analysis of hyperparameters for deep learning-based churn prediction in the banking sector. Computation 2021, 9, 34. [CrossRef]
27. Brownlee, J. *Data Preparation for Machine Learning: Data Cleaning, Feature Selection, and Data Transforms in Python*; Machine Learning Mastery: San Francisco, CA, USA, 2020.
28. Khalid, S.; Khalil, T.; Nasreen, S. A survey of feature selection and feature extraction techniques in machine learning. In Proceedings of the 2014 Science and Information Conference, London, UK, 27–29 August 2014; IEEE: Manhattan, NY, USA, 2014.
29. Saarela, M.; Jauhiainen, S. Comparison of feature importance measures as explanations for classification models. SN Appl. Sci. 2021, 3, 1–12. [CrossRef]